S Konitsiotis
Overview
Explore the profile of S Konitsiotis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
479
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kostikis N, Rigas G, Tachos N, Konitsiotis S, Fotiadis D
Annu Int Conf IEEE Eng Med Biol Soc
. 2020 Oct;
2020:4156-4159.
PMID: 33018913
The aim of this work is to implement and validate an automated method for the localization of body-worn inertial sensors. Often, body-sensor networks with inertial measurement units (IMU) used in...
2.
Timotijevic L, Hodgkins C, Banks A, Rusconi P, Egan B, Peacock M, et al.
BMC Med Inform Decis Mak
. 2020 Feb;
20(1):34.
PMID: 32075633
Background: Despite the established evidence and theoretical advances explaining human judgments under uncertainty, developments of mobile health (mHealth) Clinical Decision Support Systems (CDSS) have not explicitly applied the psychology of...
3.
Katsanos A, Kosmidou M, Konitsiotis S, Tsivgoulis G, Fiolaki A, Kyritsis A, et al.
Acta Neurol Scand
. 2017 Sep;
137(1):142-148.
PMID: 28948600
Objective: We performed a systematic review and meta-analysis to evaluate the proposed association of restless legs syndrome (RLS) with cerebrovascular/cardiovascular outcomes. Methods: We calculated the corresponding odds ratios on the...
4.
Kastanioudakis I, Konitsiotis S, Asproudis I, Ziavra N
Hippokratia
. 2014 Jul;
17(4):383.
PMID: 25031526
No abstract available.
5.
Chondrogiorgi M, Tatsioni A, Reichmann H, Konitsiotis S
Eur J Neurol
. 2013 Dec;
21(3):433-40.
PMID: 24313869
Background And Purpose: Dopamine agonists (DAs) are generally considered to be deprived of the highly dyskinetic effect of levodopa in Parkinson's disease (PD) patients. However, the risk for dyskinesia induced...
6.
Tzarouchi L, Zikou A, Tsifetaki N, Astrakas L, Konitsiotis S, Voulgari P, et al.
AJNR Am J Neuroradiol
. 2013 Nov;
35(4):680-5.
PMID: 24184520
Background And Purpose: Histopathologic studies have demonstrated WM damage in primary Sjögren syndrome. The purpose of this study was to evaluate WM microstructural changes by use of DTI-derived parameters in...
7.
Stathis P, Smpiliris M, Konitsiotis S, Mitsikostas D
Eur J Neurol
. 2012 Nov;
20(3):527-533.
PMID: 23145482
Background And Purpose: Nocebo refers to adverse events (AEs) generated by patient's negative expectations that medical treatment will likely harm instead of heal and can be assessed in placebo-controlled randomized...
8.
Margariti P, Astrakas L, Tsouli S, Hadjigeorgiou G, Konitsiotis S, Argyropoulou M
AJNR Am J Neuroradiol
. 2011 Dec;
33(4):667-72.
PMID: 22173758
Background And Purpose: The pathophysiology of eRLS has not yet been elucidated. The purpose of the study was to assess, in patients with eRLS, the volume, iron content, and activation...
9.
Maranis S, Tsouli S, Konitsiotis S
Prog Neuropsychopharmacol Biol Psychiatry
. 2011 Jun;
35(8):1795-807.
PMID: 21645577
Patients with advanced Parkinson's disease (PD) are known to develop motor complications after a few years of levodopa (L-dopa) therapy. Motor fluctuations develop with increasing severity of the disease, owing...
10.
Stathis P, Konitsiotis S, Tagaris G, Peterson D
Mov Disord
. 2011 Mar;
26(2):264-70.
PMID: 21412833
The efficacy and safety of levetiracetam (LEV), administered for management of levodopa-induced dyskinesias (LID) in Parkinson's disease (PD), was examined using a multicenter, double-blind, placebo-controlled, parallel groups, crossover trial. Because...